USD 7.04
(1.15%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -707.09 Million USD | 19.02% |
2022 | -873.2 Million USD | 42.81% |
2021 | -1.52 Billion USD | -319.73% |
2020 | -363.79 Million USD | 23.97% |
2019 | -478.52 Million USD | 0.0% |
2001 | -902.53 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -280.45 Million USD | 54.35% |
2024 Q1 | -609.27 Million USD | 13.83% |
2023 FY | -707.09 Million USD | 19.02% |
2023 Q4 | -707.09 Million USD | -9.53% |
2023 Q2 | -694.84 Million USD | 13.36% |
2023 Q1 | -801.98 Million USD | 8.16% |
2023 Q3 | -645.58 Million USD | 7.09% |
2022 Q4 | -873.2 Million USD | 29.74% |
2022 Q3 | -1.24 Billion USD | 6.25% |
2022 Q2 | -1.32 Billion USD | 9.56% |
2022 FY | -873.2 Million USD | 42.81% |
2022 Q1 | -1.46 Billion USD | 4.02% |
2021 Q1 | 14.52 Million USD | 103.99% |
2021 FY | -1.52 Billion USD | -319.73% |
2021 Q4 | -1.52 Billion USD | 11.37% |
2021 Q3 | -1.72 Billion USD | -10656.06% |
2021 Q2 | 16.32 Million USD | 12.39% |
2020 FY | -363.79 Million USD | 23.97% |
2020 Q1 | 495.28 Million USD | 0.0% |
2020 Q4 | -363.79 Million USD | 0.0% |
2019 FY | -478.52 Million USD | 0.0% |
2001 FY | -902.53 Million USD | 0.0% |
2001 Q4 | -1.52 Billion USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
ADC Therapeutics SA | -154.22 Million USD | -358.494% |
Alto Neuroscience, Inc. | 68.91 Million USD | 1126.038% |
Annovis Bio, Inc. | -5.75 Million USD | -12187.201% |
Biohaven Pharmaceutical Holding Company Ltd. | -218.84 Million USD | -223.106% |
Nuvation Bio Inc. | -38.64 Million USD | -1729.859% |
Nuvation Bio Inc. | -38.64 Million USD | -1729.859% |
Arcus Biosciences, Inc. | -116 Million USD | -509.564% |
Zymeworks Inc. | -130.83 Million USD | -440.447% |